US Patent

US11478533 — Semaglutide for use in medicine

Method of Use · Assigned to Novo Nordisk AS · Expires 2040-05-13 · 14y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of semaglutide in medical therapy for treating non-alcoholic steatohepatitis.

USPTO Abstract

The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3861`	—	Ozempic
`U-3861`	—	Ozempic
`U-3861`	—	Ozempic
`U-3861`	—	Ozempic
`U-3861`	—	Ozempic

Patent Metadata

Patent number: US11478533
Jurisdiction: US
Classification: Method of Use
Expires: 2040-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.